Precision T-cell therapy shows promise against treatment-resistant cancers in early clinical trial
Source Summary
Early clinical trial results for invikafusp alfa (invika), a precision T-cell therapy, suggest the drug may effectively treat cancers resistant to standard interventions and immunotherapy. The trial represents the first human evaluation of this therapeutic approach for managing difficult-to-treat malignancies.
Why it matters
Treatment-resistant cancers represent a significant clinical challenge; early evidence that a new T-cell therapy can manage such cases could expand options for patients who have exhausted standard and immunotherapy approaches.
